Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,761.01 65.00 0.29%

Swissmedic Approves Zonegran® (zonisamide) Monotherapy Treatment for Epilepsy



Swissmedic Approves Zonegran® (zonisamide) Monotherapy Treatment for Epilepsy

  PR Newswire

  HATFIELD, England, July 11, 2013

HATFIELD, England, July 11, 2013 /PRNewswire/ --

Zonegran ^® (zonisamide) has today been approved by Swissmedic, the Swiss
agency for the authorisation and supervision of therapeutic products, for the
monotherapy treatment of partial seizures (with or without secondary
generalisation) in adults with newly diagnosed epilepsy. Monotherapy is when
treatment is given with one single drug.

Already a successful add-on therapy, once-daily zonisamide is a second
generation anti-epileptic drug (AED) with multiple mechanisms of action and a
chemical structure which is unrelated to any other AEDs. ^[1] For patients
with newly diagnosed epilepsy, monotherapy is the preferred option for
managing their condition as this reduces the potential for adverse drug
interactions and encourages treatment compliance. ^[2]

"Monotherapy is the optimal treatment approach for managing epilepsy and
therefore the availability of zonisamide in this setting will provide newly
diagnosed epilepsy patients with access to this already proven treatment as a
first-line option in their care pathway," commented Professor Michel Baulac,
Head of Neurology, Université Paris VI.

Epilepsy is one of the most common neurological conditions in the world ^[3]
with an estimated 70,000 people living with the condition in Switzerland alone
^[4] . The successful treatment of partial-onset seizures (the most common
type of epilepsy) remains a significant challenge and up to 30% of patients
fail to achieve seizure freedom with existing AEDs ^[5] .

"The approval of zonisamide monotherapy in Switzerland is a very welcome
advance for both doctors and patients. The new extended monotherapy indication
for Zonegran will provide patients with an alternative option to help improve
their seizure control. The monotherapy indication will become an increasingly
important option in the early treatment of partial epilepsy," said Dr.
Christiane Kordeuter, Medical Director, Eisai Switzerland. "Zonegran is one of
only six AEDs available as monotherapy, allowing doctors to tailor treatment
to individual patient needs."

The efficacy and safety of zonisamide as monotherapy has been demonstrated in
a double-blind, randomised, multicentre study of 583 newly diagnosed adult
partial epilepsy patients, which compared the efficacy and safety of
once-daily zonisamide with twice-daily controlled release carbamazepine as
monotherapy. The study's primary endpoint was the proportion of seizure-free
patients at six months. Zonisamide demonstrated high response rates for
achieving seizure freedom in newly diagnosed patients with epilepsy, ^[ ^6]
similar to controlled release carbamazepine. In the majority of patients,
seizure freedom was achieved at the target dose of 300 mg. Zonisamide was
considered non-inferior to carbamazepine, was well tolerated and had no
apparent safety concerns after one year of treatment at doses ranging from 300
to 500 mg/day.

The continued development of zonisamide underscores Eisai's human health care
mission, the company's commitment to innovative solutions in disease
prevention, cure and care for the health and well being of people worldwide.
Eisai is committed to the therapeutic area of epilepsy and addressing the
unmet medical needs of patients with epilepsy and their families. Eisai is
proud to currently market more epilepsy products in EMEA than any other
company.

About Zonegran (zonisamide)

Zonisamide is licensed in Europe as monotherapy in the treatment of partial
seizures, with or without secondary generalisation, in adults with newly
diagnosed epilepsy. In addition, zonisamide is also indicated as adjunctive
therapy in the treatment of partial seizures (with or without generalisation)
in adults with epilepsy. It has a broad spectrum of anti-epileptic modes of
action and has no appreciable effects on steady-state plasma concentrations of
other AEDs, such as phenytoin, carbamazepine and valproate. ^[ ^1 ^] Zonegran
is one of only four AEDs with level A efficacy/effectiveness evidence as
initial monotherapy for adults with partial onset seizures. ^[7]

Zonisamide is available in 25mg, 50mg, and 100mg capsule strengths. In the
first two weeks, the recommended daily dose for monotherapy use is 100mg/day.
In the third and fourth weeks the dose may be increased to 200 mg daily and
then increased to 300mg daily after the next two weeks. ^[ ^1 ^]

For more information please visit: http://www.eisai.co.uk

About Epilepsy

Epilepsy is one of the most common neurological conditions in the world,
affecting approximately eight in 1,000 people in Europe, ^[8] and an estimated
50 million people worldwide. ^[ ^3 ^] Epilepsy is a chronic disorder of the
brain that affects people of all ages. It is characterised by abnormal
discharges of neuronal activity causing seizures. Seizures can vary in
severity, from brief lapses of attention or jerking of muscles, to severe and
prolonged convulsions. Depending on the seizure type, seizures may be limited
to one part of the body, or may involve the whole body. Seizures can also vary
in frequency from less than one per year, to several per day. Epilepsy has
many possible causes but often the cause is unknown.

About Eisai Europe in Epilepsy

Eisai is committed to developing and delivering highly beneficial new
treatments to help improve the lives of people with epilepsy. The development
of AEDs is a major strategic area for Eisai in Europe, the Middle East,
Africa, Russia and Oceania (EMEA).

In the EMEA region, Eisai currently has four marketed treatments including:

  * Zonegran ^® (zonisamide) as monotherapy and adjunctive therapy in adult
    patients with partial-onset seizures, with or without secondary
    generalisation. (Zonegran is under license from the originator Dainippon
    Sumitomo Pharma).
  * Zebinix ^® (eslicarbazepine acetate) as adjunctive therapy in adult
    patients with partial-onset seizures, with or without secondary
    generalisation. (Zebinix is under license from BIAL).
  * Inovelon ^® (rufinamide) for the adjunctive treatment of seizures
    associated with Lennox-Gastaut Syndrome in patients >4 years
  * Fycompa ^® (perampanel) for use as an adjunctive treatment for partial
    onset seizures, with or without secondarily generalised seizures, in
    patients with epilepsy aged 12 years and older

About Eisai

Eisai is one of the world's leading research and development (R&D) based
pharmaceutical companies and we define our corporate mission as "giving first
thought to patients and their families and to increasing the benefits health
care provides," which we call human health care ( hhc ).

Eisai concentrates its R&D activities in three key areas:

.

  * Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
    loss
  * Oncology including: anticancer therapies; tumour regression, tumour
    suppression, antibodies, etc
  * Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
    arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of
Japan, Eisai employs more than 10,000 people worldwide. From its Knowledge
Centre in Hatfield, UK, Eisai has recently expanded its business operations to
include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA
has sales and marketing operations in over 20 markets, including the United
Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria,
Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands,
Belgium, the Middle East and Russia.

For further information please visit our web site http://www.eisai.co.uk

References

1. Zonegran Summary of Product Characteristics [ http://emc.medicines.org.uk ]
January 2013, http://www.swissmedicinfo.ch

2. St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The
Initial Approach in Epilepsy Management (2009) &(2): 77 - 72

3. ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care
in Europe 2010. Available at;
http://www.ilae-epilepsy.org/Visitors/Documents/EUROReport160510.pdf (A cc
essed June 2011)

4. EPI Swiss Epilepsy Centre. Available at:
http://www.swissepi.ch/web/swe.nsf/swe__swebasdocs/epi_klinik_kurzinfo_englisch?OpenDocument
(A cc essed August 2011)

5. Kwan P, Brodie MJ Early identification of refractory epilepsy. New England
Journal of Medicine 2000; 342:314-9

6. Baulac, M. Efficacy and tolerability of zonisamide versus
controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase
3, randomised, double-blind, non-inferiority trial. Lancet Neurology (2012),
11 (7) 579 - 588

7. Glauser T. et al. Updated ILAE evidence review of antiepileptic drug
efficacy and effectiveness as initial monotherapy for epileptic seizures and
syndromes.

8. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with
economic modeling. Epilepsia 2007: 48(12) 2224 - 2233.

 

Date of preparation: July 2013

Job code: Zonegran-EU0033

Contact: Media Enquiries: Eisai Europe Ltd, Cressida Robson / Charlotte
Andrews, +44(0)7908 314 155/ +44(0)7947-231-513, Cressida_Robson@eisai.net ,
Charlotte_Andrews@eisai.net ; Tonic Life Communications, Siobhan Reilly/Nicola
Lilley, +44(0)20-7798-999, +44(0) 207-798-9905, siobhan.reilly@toniclc.com ,
nicola.lilley@toniclc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement